Two California doctors became the latest to prove that trading on insider information does not pay, and in fact, results in great losses.
Two California doctors became the latest to prove that trading on insider information does not pay, and in fact, results in great losses.
The Securities and Exchange Commission (SEC) on 19 May asserted that Drs Franklin Chu and Daniel Lama were privy to the fact the FDA in February 2012 was placing a clinical hold on the Phase II studies of GTx's Capesaris (GTx-758), an experimental non-steroidal selective estrogen
Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
